Clinical Study for Patients With Hypertension Associated With Dyslipidemia

Multi-institutional, Randomized, Double-Blind, Placebo-Control, Factorial Design, 4-arms, 8 Week Administration, Phase 3 Clinical Study for Patients With Hypertension Associated With Dyslipidemia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01764295

Enrollment

150

Registered

2013-01-09

Start date

2012-09-30

Completion date

2013-07-31

Last updated

2013-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia, Hypertension

Brief summary

The purpose of this study is to evaluate the efficacy and safety of DWJ1276

Interventions

DRUGDWJ1276

DRUGOlmesartan

DRUGRosuvastatin

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Adult male and female in between ages of 20 and 80 at the time of screening * Subject who can understand information provided and who can sign written consent voluntarily

Exclusion criteria

* Patients with hypersensitivity to olmesartan and rosuvastatin * Pregnant or lactating women and fertile women who is not using proper contraceptive method * Patient with history of drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame
LDL-C percent change of DWJ1276 from baseline	8weeks
DBP change of DWJ1276 from baseline	8weeks

Secondary

Measure	Time frame
Proportion of subjects who reached LDL-C treatment goal defined by NCEP ATP III guideline	8weeks
Proportion of subjects who reached blood pressure treatment goal defined by JNC VII report	8weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026